journal article·2025-08-13

Biomimetic Targeted Nanoplatform Exerts a Combined Effect of Alleviating Calcium Overload and Scavenging ROS to Attenuate the Inflammatory Response in Myocardial Ischemia-Reperfusion Injury

Lin Liu, Shimiao Wu, Jingya Xiu, Yang Liu, Bingrong Hong, Yihong Peng, Lingao Yin, Yilin Song, Ziqi Li, Ziyun Lin, Degong Yang, Chunrong Yang

ACS Applied Materials & Interfaces· Volume 17· Issue 32
Publisher page

Abstract

The myocardial ischemia-reperfusion injury (MIRI) is an acute and serious disease with complex pathogenesis, which is intricately associated with oxidative stress, calcium overload, and inflammation. Currently, widely utilized antioxidant or anti-inflammatory strategies present challenges in effectively reversing tissue damage. In this study, a biomimetic targeted mesoporous polydopamine nanoparticle (MR/B@PM) loaded with rapamycin (RAPA) and calcium chelating agent (BAPTA-AM) was successfully constructed, and precise delivery was achieved by a platelet membrane (PM). MR/B@PM facilitated targeted delivery to cardiomyocytes (26-fold) and enhanced intracellular uptake (1.75-fold) compared to MR/B, which was mainly attributed to the natural infarct homing ability of PM and the high affinity between PM and myocardial cells. MR/B@PM significantly inhibited 85.78% of hypoxia-reoxygenation (H/R)-induced cell apoptosis and exerted favorable inhibitory effects on myocardial injury with reduced CK-MB and LDH to 7.61 and 19.43 pg/mL compared to the H/R group. It was proved that MPDA acted as a combined effect with BAPTA-AM and RAPA to inhibit cardiomyocyte apoptosis and modulate the inflammatory response by scavenging ROS and reducing calcium overload. And in the MIRI rat model, MR/B@PM has been demonstrated to significantly reduce serum levels of CK-MB and LDH, while effectively suppressing inflammatory responses. Notably, MR/B@PM effectively reduced infarct size to 19.51% and prevented cardiac remodeling caused by MIRI. This designed nanoplatform comprehensively regulated the multiple pathogenesis of MIRI, which provided an effective strategy and mechanism for the treatment of MIRI.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Cardiac Ischemia and Reperfusion · Nanoplatforms for cancer theranostics · Neutrophil, Myeloperoxidase and Oxidative Mechanisms

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmacy, Shantou University Medical College, No. 22 Xinling Road, Shantou 515041, China

Department of Pharmacy

The Second Affiliated Hospital of Shantou University Medical College

Chifeng University Affiliated Hospital

College of Pharmacy, Jiamusi University, 258 Xuefu Road, Jiamusi 154007, China

Department of Pharmacy, Department of Dermatology

The First Affiliated Hospital of Shantou University Medical College

Funding

Basic and Applied Basic Research Foundation of Guangdong Province · National Natural Science Foundation of China · Shantou University Medical College

References (50)

Show source-provided references
1. 10.1021/acsnano.2c1004310.1021/acsnano.2c10043 ↗
2. 10.1021/acsami.2c1111710.1021/acsami.2c11117 ↗
3. 10.1021/cb400090d10.1021/cb400090d ↗
4. 10.1016/j.actbio.2022.02.01810.1016/j.actbio.2022.02.018 ↗
5. 10.1021/acsnano.3c1078410.1021/acsnano.3c10784 ↗
6. 10.1016/j.jconrel.2022.11.05710.1016/j.jconrel.2022.11.057 ↗
7. 10.7150/thno.4483610.7150/thno.44836 ↗
8. 10.1016/j.pscia.2023.10001710.1016/j.pscia.2023.100017 ↗
9. 10.1002/advs.20230212310.1002/advs.202302123 ↗
10. 10.1002/adhm.20200212110.1002/adhm.202002121 ↗
11. 10.3390/antiox1207139610.3390/antiox12071396 ↗
12. 10.1016/j.tcm.2022.02.00510.1016/j.tcm.2022.02.005 ↗
13. 10.1016/j.cej.2025.16083310.1016/j.cej.2025.160833 ↗
14. 10.1016/j.jconrel.2025.11368310.1016/j.jconrel.2025.113683 ↗
15. 10.1002/anie.20230557610.1002/anie.202305576 ↗
16. 10.1016/j.mtnano.2022.10024010.1016/j.mtnano.2022.100240 ↗
17. 10.1039/D2TB00841F10.1039/D2TB00841F ↗
18. 10.1016/j.apsb.2021.10.02710.1016/j.apsb.2021.10.027 ↗
19. 10.1021/acsami.1c0342110.1021/acsami.1c03421 ↗
20. 10.1016/j.ymthe.2018.02.01910.1016/j.ymthe.2018.02.019 ↗
21. 10.1021/acs.molpharmaceut.4c0024910.1021/acs.molpharmaceut.4c00249 ↗
22. 10.1016/j.omtn.2020.08.00710.1016/j.omtn.2020.08.007 ↗
23. 10.1016/j.ijpharm.2024.12409310.1016/j.ijpharm.2024.124093 ↗
24. 10.1016/j.jconrel.2020.01.04810.1016/j.jconrel.2020.01.048 ↗
25. 10.1002/smll.20220693610.1002/smll.202206936 ↗
26. 10.1016/j.cclet.2023.10843410.1016/j.cclet.2023.108434 ↗
27. 10.1002/advs.20220744810.1002/advs.202207448 ↗
28. 10.1021/acsnano.4c0536910.1021/acsnano.4c05369 ↗
29. 10.1002/advs.20241088910.1002/advs.202410889 ↗
30. 10.1016/j.ijpharm.2021.12039510.1016/j.ijpharm.2021.120395 ↗
31. 10.1002/advs.20210078710.1002/advs.202100787 ↗
32. 10.1161/hc3801.09558810.1161/hc3801.095588 ↗
33. 10.1161/01.CIR.0000015700.27754.6F10.1161/01.CIR.0000015700.27754.6F ↗
34. 10.1016/S0735-1097(97)00510-X10.1016/S0735-1097(97)00510-X ↗
35. 10.7150/thno.5249610.7150/thno.52496 ↗
36. 10.1063/5.008844710.1063/5.0088447 ↗
37. 10.1002/adfm.20180356710.1002/adfm.201803567 ↗
38. 10.34133/bmr.006110.34133/bmr.0061 ↗
39. 10.1021/acsami.2c0352310.1021/acsami.2c03523 ↗
40. 10.1016/j.jconrel.2023.04.01410.1016/j.jconrel.2023.04.014 ↗
41. 10.1002/advs.20180078110.1002/advs.201800781 ↗
42. 10.1016/j.actbio.2023.09.03810.1016/j.actbio.2023.09.038 ↗
43. 10.1021/acsami.4c1003210.1021/acsami.4c10032 ↗
44. 10.1016/j.biomaterials.2022.12144810.1016/j.biomaterials.2022.121448 ↗
45. 10.1021/acsnano.2c0528610.1021/acsnano.2c05286 ↗
46. 10.1016/j.mattod.2023.03.02410.1016/j.mattod.2023.03.024 ↗
47. 10.1016/j.jcis.2024.12.16310.1016/j.jcis.2024.12.163 ↗
48. 10.1021/acsnano.8b0197710.1021/acsnano.8b01977 ↗
49. 10.1038/nm.401710.1038/nm.4017 ↗
50. 10.1016/j.addr.2023.11489510.1016/j.addr.2023.114895 ↗